Comparison Of Leading COVID-19 Vaccine Candidates For U.S. Vaccine Distribution

Updated March 2021

This quick reference guide compares the following leading COVID-19 vaccines and vaccine candidates in terms of administration, efficacy, ancillary supplies, and other key factors.

Vaccine Efficacy
  • Pfizer/BioNTech: 95%
  • Moderna: 94.5%
  • AstraZeneca: Testing showed 90% for initial half-strength dose, 62% for two standard-dose shots
  • Johnson & Johnson: 72%
  • Novavax: Unknown
  • Sanofi/GlaxoSmithKline: In 2020, Sanofi/GSK announced disappointing results for people over 50 and planned to start a new Phase 2 trial in 2021 with different formulation

Download the PDF for further details such as vaccine names, vaccine types, distribution, storage, and more.

Download PDF

See Also

/am/images/4Q/markets/vaccine/vaccination-individual-500x400.jpg
Flu Vaccine
Webinar Recording🔓︎
Preparing for the 2024-2025 Flu Season
9/19/2024
Read More >
/am/images/4Q/markets/vaccine/vaccine-distribution-500x400.jpg
Flu Vaccine
Research & Advocacy
Flu Vaccine Supply Chain Resources
8/14/2024
Read More >
/am/images/4Q/webcards/influenza-vaccine-2022-webcard.jpg
Infectious Diseases
Market Report
Influenza Vaccine Market Report
11/21/2023
Read More >